Oral immunization: An update

Current Opinion in Gastroenterology

Volumn 24, Issue 6, 2008, Pages 713-719

  Mestecky, Jiri ^a   Nguyen, Huan ^a,b   Czerkinsky, Cecil ^b   Kiyono, Hiroshi ^a,c  

^a University of Alabama at Birmingham   (United States)

^b International Vaccine Institute   (South Korea)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

IgA; Mucosal vaccines; Plant vaccines; Secretory antibodies

Indexed keywords

ADENOVIRUS VECTOR; ADJUVANT; CARBOXYMETHYLCELLULOSE; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; DIPHTHERIA VACCINE; DNA VACCINE; ENTEROTOXIN; ESCHERICHIA COLI VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; LIPOPEPTIDE; LIPOPOLYSACCHARIDE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MURAMYL DIPEPTIDE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE; ROTAVIRUS VACCINE; SHIGELLA VACCINE; TYPHOID VACCINE; VACCINE; WART VIRUS VACCINE;

DIPHTHERIA; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ESCHERICHIA COLI; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INFLUENZA; INTESTINE ABSORPTION; INTESTINE INFECTION; MEASLES; MENINGOCOCCOSIS; MUCOSAL IMMUNITY; NONHUMAN; POLIOMYELITIS; REVIEW; SALMONELLA TYPHI; SHIGELLA; STREPTOCOCCUS INFECTION; VERRUCA VULGARIS;

ADMINISTRATION, ORAL; ANIMALS; BACTERIAL INFECTIONS; GASTROINTESTINAL DISEASES; HUMANS; IMMUNIZATION; INTESTINAL MUCOSA; VACCINES;

EID: 55749098495     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32830d58be     Document Type: Review

References (54)

1. Mestecky J, Bienenstock J, McGhee JR, et al. Historical aspects of mucosal immunology. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Streber W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/ Academic Press; 2005. p. xxxiii-lvi.
2. Boyaka PN, McGhee JR, Czerkinsky C, Mestecky J. Mucosal vaccines: an overview. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/ Academic Press; 2005. pp. 855-873.
3. Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 2002; 14:666-672.
4. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:S45-S53.
5. Czerkinsky C, Anjuere F, McGhee JR, et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 1999; 170:197-222.
6. Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J Immunol 2007; 179:5633-5638. The most recent experimental data and possible negative effects of oral immunization for the induction of CTL are critically analyzed.
7. Mowat AM, Faria AMC, Weiner HL. Oral tolerance. Physiological basis and clinical applications. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. London: Elsevier/Academic Press; 2005. pp. 487-537.
8. Jackson S, Mestecky J, Moldoveanu Z, Spearman P. Appendix I: Collection and processing of human mucosal secretions. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/Academic Press; 2005. pp. 1829-1839.
9. Wright PF, Kozlowski PA, Rybczyk GK, et al. Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 2002; 18:1291-1300.
10. Hemmings WA, editor. Antigen absorption by the gut. Baltimore, Maryland, USA: University Park Press; 1978.
11. Michalek SM, O'Hagan DT, Childers NK, et al. Antigen delivery systems I: nonliving microparticles, liposomes, and immune stimulating complexes (ISCOMs). In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/ Academic Press; 2005. pp. 987-1007.
12. O'Hagan DT. Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations. Clin Pharmacokinet 1992; 22:1-10.
13. Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/Academic Press; 2005. pp. 967-986.
14. Krieg AM. CpG oligodeoxynucleotides for mucosal vaccines. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/Academic Press; 2005. pp. 959-965.
15. Curtiss R III. Antigen delivery systems II: development of live recombinant attenuated bacterial antigen and DNA vaccine delivery vector vaccines. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/Academic Press; 2005. pp. 1009-1037.
16. Rosenthal KL. Recombinant live viral vectors as vaccines for mucosal immunity. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/ Academic Press; 2005. pp. 1039-1051.
17. Tucker SN, Tingley DW, Scallan CD. Oral adenoviral-based vaccines: historical perspective and future opportunity. Expert Rev Vaccines 2008; 7:25-31. Adenovirus has been considered as one of the best candidate viral vectors for both mucosal immunization and gene delivery systems. This most recent review provides advantages, as well as problems, connected with adenovirus-based approaches.
18. Savage DC. Mucosal microbiota. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/Academic Press; 2005. pp. 19-33.
19. Wright PF, Mestecky J, McElrath MJ, et al. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004; 189:1221-1231.
20. Streatfield SJ, Howard JA. Plant-based vaccine, Int J Parasitol 2003; 33:479-493.
21. Walmsley AM, Arntzen CJ. Plants for delivery of edible vaccines. Curr Opin Biotechnol 2000; 11:126-129.
22. Kunisawa J, McGhee JR, Kiyono H. Mucosal S-IgA enhancement: development of safe and effective mucosal adjuvants and mucosal antigen delivery vehicles. In: Charlotte A, Kaetzel S, editors. Mucosal immune defense: immunoglobulin A. New York: Kluwer Academic/Plenum Publishers; 2007. pp. 345-389. A critical analysis of mucosal adjuvants and mucosal delivery systems.
23. Haq TA, Mason HS, Clements JD, Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995; 268:714-716.
24. Mason HS, Chikwamba R, Santi L, et al. Transgenic plants for mucosal vaccines. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/ Academic Press; 2005. pp. 1053-1060.
25. Arakawa T, Yu J, Chong DK, et al. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 1998; 16:292-297.
26. Walmsley AM, Arntzen CJ. Plant cell factories and mucosal vaccines. Curr Opin Biotechnol 2003; 14:145-150.
27. Streatfield SJ, Jilka JM, Hood EE, et al. Plant-based vaccines: unique advantages. Vaccine 2001; 19:2742-2748.
28. Abe Y, Shimizu N, Okawa K. Prevention of contamination of uruchi-grain into mochi-rice line -1- Influence of planting distance and formation of ears (translation of Japanese title). Res Bull Aichi Agric Res Centr 1978; A10: 37-43.
29. Yamagata H, Tanaka K. The site of synthesis and accumulation of rice storage proteins. Plant Cell Physiol 1986; 27:135-145.
30. Katsube T, Kurisaka N, Ogawa M, et al. Accumulation of soybean glycinin and its assembly with the glutelins in rice. Plant Physiol 1999; 120:1063-1074.
31. Nochi T, Takagi H, Yuki Y, et al. From the cover: rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci U S A 2007; 104:10986-10991. In this report, novel strategies for the expression of antigens in rice are described and the advantages of this delivery system are discussed.
32. Neutra MR, Kraehenbuhl J-P. Cellular and molecular basis for antigen transport across epithelial barriers. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/Academic Press; 2005. pp. 111-130.
33. Manocha M, Pal PC, Chitralekha KT, et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex europaeus-I lectin as M cell target. Vaccine 2005; 23:5599-5617.
34. Wang X, Kochetkova I, Haddad A, et al. Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope. Vaccine 2005; 23:3836-3842.
35. Higgins LM, Lambkin I, Donnelly G, et al. In vivo phage display to identify M cell-targeting ligands. Pharm Res 2004; 21:695-705.
36. Clark MA, Hirst BH, Jepson MA. M-cell surface betal integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells. Infect Immun 1998; 66:1237-1243.
37. Kandori H, Hirayama K, Takeda M, Doi K. Histochemical, lectin-histochemical and morphometrical characteristics of intestinal goblet cells of germfree and conventional mice. Exp Anim 1996; 45:155-160.
38. Nochi T, Yuki Y, Matsumura A, et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 2007; 204:2789-2796. This paper describes new possibilities for an increased targeting of antigens to intestinal M cells involved in the uptake of vaccines to generate superior immune responses.
39. Herrmann JE, Robinson HL. DNA vaccines for mucosal immunity to infectious diseases. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunoglobulins, 3rd ed. Amsterdam: Elsevier/ Academic Press; 2005. pp. 1071-1084.
40. Raska M, Moldoveanu Z, Novak J, Hel Z, et al. Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. Vaccine 2008; 26:1541-1551.
41. Lundholm P, Leandersson AC, Christensson B, et al. DNA mucosal HIV vaccine in humans. Virus Res 2002; 82:141-145.
42. Kabir S. Cholera vaccines: the current status and problems. Rev Med Micro 2005; 16:101-116.
43. Levine MM, Ferreccio C, Abrego P, et al. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17:S22-S27.
44. Kantele A, Hakkinen M, Moldoveanu Z, Lu A, et al. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun 1998; 66:5630-5635.
45. Ward RL. Rotavirus vaccines: how they work or don't work. Expert Rev Mol Med 2008; 10:e5. Current evaluation of rotavirus vaccines with a detailed description of their composition, induction of immune responses, and potential complications.
46. Underdown BJ. Parenteral immunization induces mucosal protection: a challenge to the mucosal immunity paradigm. In: Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W, editors. Mucosal immunology, 3rd ed. Amsterdam: Elsevier/Academic Press; 2005. pp. 831-840.
47. Russell MW, Lue C, van den Wall Bake AW, et al. Molecular heterogeneity of human IgA antibodies during an immune response. Clin Exp Immunol 1992; 87:1-6.
48. Lue C, Tarkowski A, Mesteoky J. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory antipneumococcal antibodies. J Immunol 1988; 140:3793-3800.
49. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-1269.
50. Passwell JH, Ashkenazi S, Harlev E, et al. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr Infect Dis J 2003; 22:701-706.
51. Ahmed A, Li J, Shiloach Y, et al. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J Infect Dis 2006; 193:515-521.
52. Passwell JH, Harlev E, Ashkenazi S, et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001; 69:1351-1357.
53. Jonard PP, Rambaud JC, Dive C, et al. Secretion of immunoglobulins and plasma proteins from the jejunal mucosa. Transport rate and origin of polymeric immunoglobulin A. J Clin Invest 1984; 74:525-535.
54. Moldoveanu Z, Oliver F, Mestecky J, Elson CO. Oral tolerance in humans: failure to suppress an existing immune response by oral antigen administration. Ann N Y Acad Sci 2004; 1029:299-309.